Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design
摘要:
Interleukin-2 inducible T-cell kinase (ITK) is a member of the Tec kinase family and is involved with T-cell activation and proliferation. Due to its critical role in acting as a modulator of T-cells, ITK inhibitors could provide a novel route to anti-inflammatory therapy. This work describes the discovery of ITK inhibitors through structure-based design where high-resolution crystal structural information was used to optimize interactions within the kinase specificity pocket of the enzyme to improve both potency and selectivity. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS [FR] DERIVES D'ACIDE THIOPHENE-2-CARBOXYLIQUE (1H-BENZIMIDAZOL-2 YL)-AMIDE ET COMPOSES ASSOCIES UTILISES COMME INHIBITEURS DE LA TEC KINASE ITK (KINASE DES LYMPHOCITES INDUCTIBLES PAR L'INTERLEUKINE -2) POUR TRAITER UNE INFLAMMATION ET DES TROUBLES IMMUNOLOGIQUES ET ALLERGIQUES
[EN] BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS<br/>[FR] DÉRIVÉS DE BENZIMIDAZOLE EN TANT QU'INHIBITEURS DE RLK ET ITK
申请人:PRINCIPIA BIOPHARMA INC
公开号:WO2015134210A1
公开(公告)日:2015-09-11
The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.
Disclosed are compounds of formula(I):
wherein Ar
1
, Ar
2
, R
1
, R
2
, R
3
, R
4
and X
a
are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising these compounds.
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
申请人:PRINCIPIA BIOPHARMA, INC.
公开号:EP3114124A1
公开(公告)日:2017-01-11
BENZIMIDAZOLE DERIVATIVES AS RLK AND ITK INHIBITORS
申请人:PRINCIPIA BIOPHARMA, INC.
公开号:US20160368908A1
公开(公告)日:2016-12-22
The present disclosure is directed to certain inhibitors of RLK and ITK of formula (I), pharmaceutical compositions comprising such compounds, and method of treating diseases mediated by inhibition of RLK and ITK.